In BriefCompanies like 23andMe and AncestryDNA already offer a method of receiving DNA insights, and they profit from giving up that data for research. Now Nebula Genomics wants you to get your fair share.
When the human genome was sequenced for the first time in 2001, the project cost $1 billion, as per a report from Nature – but today, individuals can undergo the same process for around $1,000, and prices are set to drop even further. Nebula Genomics, a start-up co-founded by genetic sequencing pioneer George Church, wants to give people an even cheaper option.
Nebula is using blockchain technology to construct a platform that lets customers reap the benefits of making their genetic information available to researchers, while maintaining their privacy.
Individuals will send a saliva sample to Nebula, which is analyzed by the company. From there, other entities are free to pay a fee to access to the genetic information for research purposes, using a secure computation platform provided by Nebula. The data can be rented out over and over again, even to more than one buyer at the same time.
The system is based around a purpose-built cryptocurrency dubbed Nebula tokens. Companies would need to buy tokens in order to pay for access to people’s genetic information, and individuals would initially pay a small fee to have their DNA sequenced using the coin. The idea is that they would get the money back as their genetic code is purchased by researchers all over the world.
The Genetic Market
In the past few years, various other services have sprung up that give people the ability to learn more about their genetic make-up.
The likes of 23andMe and AncestryDNA don’t offer full genome sequencing, but they do use a similar business model in that customers are asked to consent for their data to be used for research purposes. Their information is then sold on, but they don’t receive any of the money.
Companies are racing to provide a cheap way for people to undergo this analysis because they want a greater insight into their background, or a better understanding of potential health risks. The data they’re amassing will be valuable for years to come, thanks to its applications in the development of new drugs and other medical research, so building up as large a database as possible now could have a huge payoff.
In an interview with The Guardian, Nebula co-founder Dennis Grishin suggested that its customers might be able to take advantage of this need for data by finding a third party (such as a research institution) willing to subsidize the initial fee.
The company hopes to have its service operational in the U.S. within the next six months, but there are some lingering questions about its privacy measures. The key is giving researchers the access they need in order to carry out their work, while still maintaining privacy and ensuring that the information can’t be exfiltrated from the system.
The computation platform at the heart of the system is crucial – and since Nebula will make its money from researchers paying to use that infrastructure, it should come as no surprise that the company is putting great efforts into making sure its security is rock solid. The startup is already collaborating with security experts that will help make sure that data are protected, anonymous and overall a good investment and research tool.